SKIP TO CONTENT
About Abbott
Contact
International | eng
Country Language

CARDIOVASCULAR

International | eng
Country Language

Diamondback 360™

Coronary Orbital Atherectomy System

Severe Calcium.
One Solution.

Diamondback 360 product
Features

Diamondback 360™ is the only atherectomy system with a diamond-coated crown that orbits 360 degrees, specifically designed to target severe calcium.

Diamondback 360™ Coronary Orbital Atherectomy System’s (OAS) unique dual mechanism of action uses differential sanding and pulsatile forces that enable simultaneous modification of both intimal and medial calcium for optimal stent delivery, expansion, and apposition in severely calcified lesions. One device treats eccentric, concentric, and nodular calcium.1-6

Diamondback 360™ OAS has a Unique Dual Mechanism of Action Design

One device reduces intimal calcium and fractures medial calcium. Differential sanding and pulsatile forces enable simultaneous modification of both intimal and medial calcium for optimal stent delivery, expansion, and apposition in severely calcified lesions.1-4
 

OCT Imaging

Watch video to learn more about the dual mechanism of action.

Diamondback 360™ OAS Gives You the Versatility to Treat Challenging Cases

Treat even the most severely calcified lesions, with under 2-minute setup7,8 and predictable procedure times.2
 

Facilitates antegrade and retrograde treatment of:

  • Long, Diffuse Lesions
    Successfully treated lesions up to 60 mm in length in real-world study.9
  • Heavily Stenosed Lesions
    Crossed >99% of lesions with <2% pre-dilatation in the ORBIT II study.1,10
  • Nodular Lesions
    Effectively treats nodular calcification.5,6
  • Ostial Lesions
    Safely treats ostial lesions.11-13
     

Low Profile

6F compatible for femoral or radial access.14
 

Multiple Vessel Sizes

A single 1.25 mm crown treats vessels 2.5 mm to 4.0mm14
 


Diamondback 360™ OAS Has Been Proven Effective and Safe in the Treatment of Severely Calcified Lesions.

Extensively studied, and with over 100,000 patients treated,15 orbital atherectomy has been demonstrated to perform effectively and safely in the treatment of severely calcified lesions.
 

 

>2,200

Patients Across 11 Robust Studies5,9

Proven Safety

<1%

Component Angiographic Complications in Two Real-world Studies9,16

Procedural Success

97.7%

Crossing and Stent Deployment in ORBIT II Study1

Low Q-Wave MI Rate

0.9%

In the ORBIT II Study at 30 days1

ORBIT II Target Lesions Revascularization (TLR)15


Sustained Clinical Performance

Data are for ORBIT II TLR in the OA+DES patient cohort.

3.4%
at 1 Year

5.1%
at 2 Years

6.6%
at 3 Years

The ORBIT II trial included patients with severely calcified lesions and demonstrated low rates of TLR at 1, 2, and 3 years.


References

  1. Chambers, J., et al., JACC Cardiovasc Interv. 2014;7(5):510-518.
  2. Shlofmitz, E., et al., Expert Rev Med Devices. 2017;14(11):867-879.
  3. Yamamoto, M., et al., Catheter Cardiovasc Interv. 2019;93(7):1211-1218.
  4. Kini, A., et al., Catheter Cardiovasc Interv. 2015;86(6):1024-1032.
  5. Shlofmitz, E., et al., Interv Cardiol. 2019;14(3):169-173.
  6. Abellas-Sequeiros, M., et al., REC Interv Cardiol. 2022;4(2):163-164.
  7. Lee, MS, et al., J Invasive Cardiol. 2016;28(4):147-150.
  8. Moses, J., Cardiac Interventions Today. 2015;May/June:75. Link accessed November 20, 2023. https://citoday.com/articles/2015-may-june/vesselpreparation-with-orbital-atherectomy-for-treating-severe-coronary-calcium-for-stent-delivery.
  9. Vinardell J, et al. J Am Coll Cardiol. 2020;76(17 Suppl S):B71.
  10. Data on file at Abbott. In the ORBIT II study, the OAS was inserted and activated in 434 subjects, but in 2 cases, the OAS was unable to cross the lesion.
  11. Lee MS, et al. J Interv Cardiol. 2018;31(1):15-20.
  12. Chambers JW, et al. Catheter Cardiovasc Interv. 2022;100(4):553-559.
  13. Ghazzal A, et al. Cardiovasc Revasc Med. 2024;58:52-57.
  14. Diamondback 360™ Coronary Orbital Atherectomy Systems Instructions for Use (IFU). Please refer to IFU for additional information.
  15. Data on file at Abbott.
  16. Lee, MS, et al., J Interv Cardiol. 2016;29(4):357-362.

MAT-2401825 v2.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
Abbott logo

Information contained herein for distribution outside the U.S. only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

MAT-2001111 v7.0

Disclaimer

You are about to enter an Abbott country- or region-specific website. 

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

Do you wish to continue and enter this website? 

YES

MAT-2305078 v1.0